Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Br J Ophthalmol. 2011 Jul;95(7):986-91. doi: 10.1136/bjo.2010.190942. Epub 2010 Dec 22.
To investigate the ability of the preferential hyperacuity perimeter test to assess responsiveness to ranibizumab therapy for exudative age-related macular degeneration (AMD).
Fourteen consecutive patients with newly diagnosed choroidal neovascularisation underwent a preferential hyperacuity perimeter metamorphopsia test (main outcome measures) 1 h before (baseline) and 1 h, 1 day, 1 week and 1 month after one intravitreal injection of ranibizumab (0.05 ml/0.5 mg). Best corrected visual acuity (BCVA) and several spectral domain optical coherence tomography (OCT) parameters (secondary outcome measures) were compared with the metamorphopsia test.
Fourteen eyes (14 patients, 78% women, mean age 83 ± 6.2 years) were included in the analysis. The mean preferential hyperacuity perimeter metamorphopsia test score improved significantly from 20.4 ± 35 at baseline to 9.2 ± 23 after the single ranibizumab injection (p < 0.05). The mean reduction in central macular thickness, maximal retinal thickness at the fovea, maximal height of subretinal fluid, maximal diameter of the largest retinal cyst and maximal height of pigment epithelial detachment, as evaluated by spectral domain OCT, closely reflected the functional improvements as evaluated by preferential hyperacuity perimeter, showing a significant correlation with metamorphopsia changes (Spearman correlation 0.9, p < 0.05). Mean BCVA improved significantly from 20/80 to 20/60 (p < 0.05). A significant correlation was also found between the mean BCVA changes and the mean metamorphopsia changes (Spearman correlation 0.97, p < 0.05). The correlation coefficient between OCT measurements and preferential hyperacuity perimeter score within subjects was 0.51 (p < 0.05).
The improvement in metamorphopsia test score after intravitreal ranibizumab injection, which correlated closely with improvement in several OCT parameters, suggests that the preferential hyperacuity perimeter test may be used to monitor the response to anti-vascular endothelial growth factor (VEGF) treatment in patients with exudative AMD.
研究偏好敏锐度周边视野检查在评估雷珠单抗治疗渗出性年龄相关性黄斑变性（AMD）中的反应能力。
14 例新诊断的脉络膜新生血管患者在接受玻璃体腔内雷珠单抗（0.05 ml/0.5 mg）注射前 1 小时（基线）和注射后 1 小时、1 天、1 周和 1 个月时接受偏好敏锐度周边视野检查（主要观察指标）。最佳矫正视力（BCVA）和几种光谱域光学相干断层扫描（OCT）参数（次要观察指标）与变形觉测试进行比较。
14 只眼（14 例患者，78%为女性，平均年龄 83±6.2 岁）纳入分析。与基线时的 20.4±35 相比，单次雷珠单抗注射后，偏好敏锐度周边视野检查（PHMP）的平均得分显著提高（20.4±35，p<0.05）。中央黄斑厚度、黄斑中心凹最大视网膜厚度、视网膜下液最大高度、最大视网膜囊肿直径和最大色素上皮脱离高度的平均减少，由光谱域 OCT 评估，与偏好敏锐度周边视野检查的功能改善密切相关，与变形觉变化具有显著相关性（Spearman 相关系数 0.9，p<0.05）。平均 BCVA 从 20/80 显著提高至 20/60（p<0.05）。也发现平均 BCVA 变化与平均变形觉变化之间存在显著相关性（Spearman 相关系数 0.97，p<0.05）。受试者内 OCT 测量值与偏好敏锐度周边视野评分的相关系数为 0.51（p<0.05）。
玻璃体腔内雷珠单抗注射后变形觉检查分数的改善与几种 OCT 参数的改善密切相关，这表明偏好敏锐度周边视野检查可能用于监测渗出性 AMD 患者抗血管内皮生长因子（VEGF）治疗的反应。
